PIB TrackerGovernment bans 16 'irrational' fixed-dose combination medicines
The Health Ministry has prohibited the manufacture, sale and distribution of 16 fixed-dose combination drugs found to lack therapeutic justification — acting under the Drugs and Cosmetics Act on a DTAB expert review ordered by the Supreme Court.
What happened
- The Ministry of Health and Family Welfare issued notifications under Section 26A of the Drugs and Cosmetics Act, 1940, prohibiting the manufacture, sale and distribution of 16 Fixed Dose Combinations (FDCs) for human use, with immediate effect.
- The decision follows Supreme Court directions mandating a comprehensive review of FDCs available in the country.
- In compliance, the Drugs Technical Advisory Board (DTAB) constituted an Expert Committee to identify FDCs that are irrational, lack therapeutic justification or may pose risks.
- The 16 FDCs span dermatological preparations, analgesic and antispasmodic medicines, and antibiotic-based formulations whose continued use was deemed not beneficial relative to the risks.
- The Ministry directed all State Drug Controllers and enforcement agencies to ensure strict compliance, in line with its push for the rational use of medicines.
For Prelims
- Fixed Dose Combination (FDC): A single dosage form combining two or more active drugs in a fixed ratio; 'irrational' FDCs combine drugs without scientific/therapeutic justification and may raise safety and antimicrobial-resistance risks.
- Section 26A: Empowers the Central Government to prohibit the manufacture, sale or distribution of a drug in the public interest under the Drugs and Cosmetics Act, 1940.
- DTAB: The Drugs Technical Advisory Board, the highest statutory advisory body on technical drug matters under the Act (under Section 5), advising the Centre and states.
- CDSCO: The Central Drugs Standard Control Organisation, headed by the Drugs Controller General of India (DCGI), is the national drug regulator; State Drug Controllers enforce at the state level.
- Precedent: The Government earlier banned 344 FDCs (2016) and 328 FDCs (2018) after Supreme Court-directed DTAB reviews — this 16-FDC ban continues that process.
- Antimicrobial resistance (AMR): Irrational antibiotic FDCs can worsen AMR; rational-use measures are part of India's AMR and patient-safety agenda.
- Don't confuse: Section 26A bans a drug in the public interest (a regulatory prohibition) — it is distinct from licensing; DTAB is an advisory board, while CDSCO/DCGI is the enforcing regulator.
For UPSC: The Health Ministry banned 16 irrational FDCs under Section 26A of the Drugs and Cosmetics Act on a DTAB expert review ordered by the Supreme Court. Anchor FDCs and 'irrational' combinations, Section 26A, the DTAB (statutory advisory) vs CDSCO/DCGI (regulator), the 2016 (344) and 2018 (328) precedents, antimicrobial resistance, and drug-safety governance.
What it is NOT: The ban is under Section 26A of the Drugs and Cosmetics Act, 1940 (power to prohibit a drug in the public interest) — not a new law. The DTAB is a statutory advisory board; the regulator that enforces drug standards is CDSCO/DCGI. An FDC ban targets specific irrational combinations, not the individual drugs taken separately.
For Mains
Syllabus: GS2.13 · GS2.9 · Linkage L2
Anchor
Drug safety and rational medicine use — regulatory action to protect public health from irrational, unjustified drug combinations.
Substantiation (data)
16 FDCs banned under Section 26A (D&C Act 1940) on a DTAB expert review per Supreme Court directions; follows the 2016 (344) and 2018 (328) FDC bans.
Exemplification
Cite the FDC bans (with CDSCO oversight and AMR concerns) as examples of evidence-based regulation strengthening patient safety.
Problematisation
Continued circulation of irrational FDCs, enforcement gaps across states, industry pushback, and self-medication challenge effective drug regulation.
Way-forward
Strengthen CDSCO/state enforcement, periodic FDC review, curb irrational antibiotic combinations to fight AMR, and improve prescriber and public awareness.
Position
Government stance: only safe, effective and scientifically validated medicines should reach the public; irrational FDCs are removed in the public interest.
Deploys into: Drug regulation & patient safety (D&C Act, DTAB/CDSCO) · rational medicine use & AMR · health governance & Supreme Court oversight (GS2.13 health sector, GS2.9 statutory & regulatory bodies).
Ministry of Health and Family Welfare · 2026-06-20 · PRID 2275595 · PIB source ↗